- Investors Re-evaluate Kidney Disease as New Cell and Gene Therapy Strategies EmergeIn a recent episode of BioSpace's Denatured podcast, the CEOs of ProKidney and Nephrogen discussed why kidney disease has long been a difficult indication for cell and gene-based medicines. The co…
- FDA approves GSK‑Ionis hepatitis B functional cure, Hibsago, targeting undetectable virus after six monthsThe FDA has approved bepirovirsen, an antisense oligonucleotide from GSK and Ionis, for chronic hepatitis B infection. It will be sold under the brand name Hibsago. The therapy is described as a f…